Free 24-hour delivery over £75 · Same-day dispatchOrder before 2pm - same-day dispatch · Free 24-hour delivery over £75
Research use only
Kovalabs supplies research-grade peptides to qualified researchers for laboratory use only. They are not medicines, are not for human or animal consumption, and are supplied with no dosing or medical guidance.
You must be 18 or over and a qualified person purchasing solely for scientific research.
Selecting ‘I agree’ confirms the above and your acceptance of our Research Disclaimer and Terms of Sale.
Research use only
· 6 min read
"Not approved" and "illegal" get treated as the same word. They are not. Retatrutide (developer code LY3437943) is an investigational compound that no medicines regulator has licensed anywhere - and it is also not a controlled drug under UK drugs law. Both statements are true at once, and the gap between them is the whole subject of this page. What follows describes regulatory classification, not any human use, benefit, or outcome; Kovalabs supplies retatrutide strictly as a research reagent for laboratory use, never for human or veterinary use.
Retatrutide is an unlicensed, investigational research compound. It is not an approved medicine, and it is not a controlled drug. It has no UK marketing authorisation, so it cannot be sold or marketed as a medicine for human use. It is also absent from the controlled-substance schedules, so it is not contraband in the way a scheduled drug would be. A research reagent occupies a third category that the "legal versus illegal" framing has no slot for, which is exactly why the question keeps getting answered badly. The classification - not a verdict on any use - is what the rest of this page sets out.
Retatrutide is a single engineered, fatty-acid-acylated peptide developed by Eli Lilly under the code LY3437943. The published literature characterises it by its receptor pharmacology: a triple agonist at the GIP, GLP-1 and glucagon receptors. Coskun et al. characterised that triple receptor activity in Cell Metabolism in 2022. On the chemistry side it carries the molecular formula C221H342N46O68 and a molecular weight of approximately 4731 g/mol, indexed under PubChem CID 171390338. None of that is a regulatory status - it is identity. The point worth holding onto is that retatrutide is grouped here by what receptors it engages, never by any indication, because the indication framing is precisely what converts a reagent into a regulated medicine.
No. Retatrutide has not been granted a marketing authorisation by the MHRA, the FDA, the EMA, or any comparable body. It sits in Eli Lilly's phase 3 clinical evaluation programme, which is the literal meaning of "investigational": a compound still being studied under trial authorisation, not one a regulator has reviewed and licensed for sale.
In the UK, medicines marketed for human use are regulated under the Human Medicines Regulations 2012. A licensed medicine has been through that framework - dossier, assessment, authorisation - and may be placed on the market with the claims its authorisation covers. An investigational compound has not. It can be lawfully used inside an authorised clinical trial, and it can be supplied as a laboratory research reagent, but it cannot be sold or presented as a medicine for human use, because doing so would require an authorisation it does not have. "Unlicensed" is therefore a precise status, not an insult: it states that the medicines-approval route has not been completed, nothing more.
No. The Misuse of Drugs Act 1971 and its schedules list the substances the UK treats as controlled drugs, with possession and supply offences attached. Retatrutide does not appear on those schedules. As an acylated peptide it is outside the chemical families the Act enumerates, so the possession-and-supply offence structure that applies to a scheduled drug simply does not engage.
The Psychoactive Substances Act 2016 is a separate instrument, and it is worth pre-empting because people reach for it whenever a compound is unfamiliar. It targets substances supplied for their psychoactive effect on the central nervous system. A peripherally-acting incretin-class receptor agonist is not what that Act was written to capture. So retatrutide is neither a controlled drug under the 1971 Act nor a psychoactive substance under the 2016 Act. Being unscheduled is not a statement that anything is safe or sanctioned for use - it is only a statement about which criminal-law schedules it does and does not appear on.
This is the distinction the whole topic turns on, so it is worth being blunt about it. "Illegal" describes something the law prohibits - a scheduled drug you may not possess, a medicine sold without the authorisation the law requires. "Investigational" describes a developmental stage: a compound under active study that no regulator has yet licensed. "Unlicensed" describes the absence of a marketing authorisation. None of those three words is a synonym for the others.
A compound can be investigational and unlicensed while still being a perfectly ordinary laboratory reagent, supplied lawfully for research and absent from every controlled-substance schedule. The error is collapsing "regulators have not approved this for human use" into "therefore it is contraband". The first is a fact about a medicines pathway; the second is a fact about criminal law; they are answered by different instruments and they do not imply each other. What does follow from the unlicensed status is narrow and real: retatrutide cannot be marketed or presented as a medicine, and a supplier who attaches a human-use or outcome claim to it has converted a research reagent into an unlicensed medicine - the one move that genuinely crosses a legal line.
The MHRA's guidance on how it decides whether a product is a medicine - long known as Guidance Note 8 - is the document that explains where the line actually sits. Its core principle is that classification follows presentation and function, not packaging. A product becomes a medicine by presentation when it is described, marketed, or implied to treat or prevent a condition, or otherwise to produce a physiological effect in a human being. The medicinal claim is what triggers regulation - and a "research use only" label cannot neutralise a benefit claim made elsewhere on the same page.
Read the other way, that is also what keeps a research reagent lawfully outside the medicines framework. A compound supplied for laboratory study, described by its receptor pharmacology and published research context, and carrying no human-use, therapeutic, or dosing claim, is not being presented as a medicine - so GN8's presentation test is not met. This is the same framework set out in our wider explainer on the research peptides UK legal position, and it is why a compliant supplier keeps the description mechanism-led from the product page through to the FAQ. In practice that is why the product record for retatrutide carries its verified chemistry identifiers and a third-party certificate of analysis for batch identity and purity rather than any indication or outcome: documented identity is part of what a legitimate research-reagent supply chain looks like, and it is the same mechanism-led approach taken in the full retatrutide research monograph. The regulated thing is the claim, not the molecule.
Retatrutide is not a controlled drug, so it is not contraband under the Misuse of Drugs Act 1971. It is an unlicensed, investigational compound that cannot be sold or marketed as a medicine for human use, and Kovalabs supplies it strictly as a research reagent for laboratory use, not for human or veterinary use.
No. Retatrutide (LY3437943) holds no UK marketing authorisation and is in Eli Lilly phase 3 clinical evaluation. It is not approved by the MHRA, FDA or EMA anywhere, which is what "investigational" and "unlicensed" mean.
No. It does not appear on the schedules of the Misuse of Drugs Act 1971, and as a peripherally-acting peptide it is not caught by the Psychoactive Substances Act 2016 either. Being unscheduled is a statement about criminal-law schedules, not an endorsement of any use.
No. "Not approved" (unlicensed/investigational) describes a medicines pathway that has not been completed; "illegal" describes something the law prohibits. They are answered by different instruments - the Human Medicines Regulations 2012 and the Misuse of Drugs Act 1971 - and one does not imply the other.
Under MHRA Guidance Note 8, presentation. Attach a human-use, therapeutic, or outcome claim to the compound and it is being presented as a medicine without the authorisation the law requires. Remove the claim and describe it by its receptor pharmacology and research context, and it stays a research reagent. The full research disclaimer sets out the terms.
Retatrutide is supplied strictly as a research reagent for laboratory use. It is not a medicine or a supplement, not for human or veterinary use, and no dose, route, schedule, or outcome is stated or implied anywhere on this page. It has not been evaluated by the MHRA, FDA or EMA, and it is investigational and unlicensed but not a controlled drug. Every batch is third-party tested with a certificate of analysis. See the full research disclaimer for the terms under which all compounds are supplied.